Skip to main content

Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide

Medically reviewed by Carmen Pope, BPharm. Last updated on July 9, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 8, 2024 -- Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA Internal Medicine.

Patricia J. Rodriguez, Ph.D., from Truveta Inc. in Bellevue, Washington, and colleagues compared on-treatment weight loss and rates of gastrointestinal adverse events among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes. After propensity score matching, 18,386 adults were included in the study.

The researchers found that participants receiving tirzepatide were significantly more likely to achieve weight loss than those receiving semaglutide (≥5, ≥10, and ≥15 percent weight loss hazard ratios: 1.76, 2.54, and 3.24, respectively). For patients receiving tirzepatide, on-treatment changes in weight were larger at three, six, and 12 months (differences, −2.4, −4.3, and −6.9 percent, respectively). The groups had similar rates of gastrointestinal adverse events.

"Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight loss and larger reductions in body weight compared with those treated with semaglutide," the authors write. "Consistent treatment effect estimates were observed in subgroups with and without type 2 diabetes."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss

FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...

In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity

TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...

GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression

MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.